{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Krakow EF"],"funding":["NCI NIH HHS"],"pagination":["1069-1082"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11406181"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["144(10)"],"pubmed_abstract":["<h4>Abstract</h4>Relapse is the leading cause of death after allogeneic hematopoietic stem cell transplantation (HCT) for leukemia. T cells engineered by gene transfer to express T cell receptors (TCR; TCR-T) specific for hematopoietic-restricted minor histocompatibility (H) antigens may provide a potent selective antileukemic effect post-HCT. We conducted a phase 1 clinical trial using a novel TCR-T product targeting the minor H antigen, HA-1, to treat or consolidate treatment of persistent or recurrent leukemia and myeloid neoplasms. The primary objective was to evaluate the feasibility and safety of administration of HA-1 TCR-T after HCT. CD8+ and CD4+ T cells expressing the HA-1 TCR and a CD8 coreceptor were successfully manufactured from HA-1-disparate HCT donors. One or more infusion"],"journal":["Blood"],"pubmed_title":["HA-1-targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantation."],"pmcid":["PMC11406181"],"funding_grant_id":["P30 CA015704","K23 CA154532"],"pubmed_authors":["Summers C","Kanaan SB","Black RG","Chapuis AG","Greenberg PD","Cunningham TM","Bleakley M","Denker AE","Biernacki MA","Gooley TA","Yeh AC","Vartanian N","Furlan SN","Yeung CCS","Brault M","Riddell SR","Till BG","Maloney DG","Bar M","Krakow EF","Dahlberg A","Cassaday RD","Woodward KB","Dossa RG","Newell EW"],"additional_accession":[]},"is_claimable":false,"name":"HA-1-targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantation.","description":"<h4>Abstract</h4>Relapse is the leading cause of death after allogeneic hematopoietic stem cell transplantation (HCT) for leukemia. T cells engineered by gene transfer to express T cell receptors (TCR; TCR-T) specific for hematopoietic-restricted minor histocompatibility (H) antigens may provide a potent selective antileukemic effect post-HCT. We conducted a phase 1 clinical trial using a novel TCR-T product targeting the minor H antigen, HA-1, to treat or consolidate treatment of persistent or recurrent leukemia and myeloid neoplasms. The primary objective was to evaluate the feasibility and safety of administration of HA-1 TCR-T after HCT. CD8+ and CD4+ T cells expressing the HA-1 TCR and a CD8 coreceptor were successfully manufactured from HA-1-disparate HCT donors. One or more infusion","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Sep","modification":"2026-05-29T19:46:38.973Z","creation":"2026-04-08T05:51:04.252Z"},"accession":"S-EPMC11406181","cross_references":{"pubmed":["38683966"],"doi":["10.1182/blood.2024024105"]}}